Form 4 for DXCM Dexcom
Accepted 2026-03-10 00:00:00 ET · period of report 2026-03-08 · accession 0001093557-26-000045 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-10 | 2026-03-08 | DXCM | Coleman Jon | EVP, Chief Commercial Off | A - Grant | $0.00 | +43.9K | 112.6K | +64% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-08 | A | A | 43,897 | $0.00 | 112,635 | D | — | — | (F1) Represents a grant of restricted stock units (RSUs) that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. RSUs represent a contingent right to receive one share of DexCom, Inc. Common Stock. (F2) Included in this number are 112,635 unvested RSUs, 43,897 of which were granted on March 8, 2026 and shall vest through March 8, 2029, and 68,738 of which were granted on May 22, 2025 and shall vest through May 22, 2029. |